Company Profile

ImaginAb Inc
Profile last edited on: 9/16/21      CAGE: 58X66      UEI: NN7GWLY4L167

Business Identifier: Immuno-oncology imaging: re-engineering antibodies into small proteins.
Year Founded
2007
First Award
2009
Latest Award
2016
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

440 Hindry Avenue Suite E
Inglewood, CA 90301
   (310) 258-2411
   info@imaginab.com
   www.imaginab.com
Location: Single
Congr. District: 43
County: Los Angeles

Public Profile

Based in Inglewood, CA but having subsidiary operations in Tokyo, Japan, ImaginAb Inc is a bio-imaging company, structured around providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. The company has developed a pipeline of imaging products that uses the specificity of monoclonal antibodies to create precise images of disease activity. Programs include a portfolio of precision imaging products, such as CD8 (IAB22M2C) and CD4 for immune-oncology; and PSMA PET (IAB2M) for prostate cancer. The effort is focused on re-engineering antibodies into smaller protein formats with kinetics optimized for diagnostic imaging. The firm is working on development of a pipeline of targeted molecular imaging agents for unmet clinical needs in oncology and immunology to include products for prostate and pancreatic cancers and is also developing companion imaging agents based on therapeutic antibody pipelines. Its technology enables a therapeutic mAb or ADC to be re-engineered into an imaging agent that has biospecificity of the ‘parent’ product with kinetics for clinical imagin

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 2 NIH $1,000,001
Project Title: Clinical Development of a Novel PET Imaging Agent for Prostate Cancer
2012 2 NIH $995,229
Project Title: Clinical Production and IND Enabling Studies for PSCA Minibody Imaging in Pancrea
2011 1 NIH $224,264
Project Title: Tas::75 0849::Tas Sbir Topic 307 Phase I Novel Imaging Agents to Expand the Clin
2009 1 NIH $199,363
Project Title: Biomedical (Basic)

Key People / Management

  Christian Behrenbruch -- Former CEO and Co-Founder

  Jennifer S Keppler -- COO

  Ian Wilson -- CEO

  Ian Wilson -- CEO

  Debbie Anderson -- Vice President, Regulatory and Quality Assurance

  Kathleen Brady -- Manager QA and Regulatory

  Roger Crystal -- Vice President, Business Development

  David Fractor -- Chief Financial Officer

  Gregory Frank -- Director Business Development

  Jean Gudas -- Vice President of Research and Development

  David T Ho -- Senior Scientist

  Ron Korn -- Chief Medical Imaging Officer

  William Le -- Vice President, Operations

  Alessandro Mascioni -- Director of Research

  Shintaro Nishimura -- Executive Director

  Ivan Plavec -- Chief Business Officer

  Jeff Quan -- Chief Financial Officer

  Robert Reiter -- Chief Medical Advisor (Co-Founder)

  Dauleti Satpaye

  Dan Shochat -- Vice President, Manufacturing

  Anna M Wu -- CSO and Co-Founder

  Brad Wyman -- Vice President, Imaging Sciences